Due to the current situation related to the coronavirus (COVID-19), study teams may experience delays in responding to signups and scheduling patients on StudyPages.A study team member will respond to you as soon as possible.

UC Davis Health Clinical Studies

Experimental Risankizumab vs. Placebo For Moderate to Severe Hidradenitis Suppurativa (painful lumps under skin)

Volunteer for research at UC Davis and contribute to discoveries that may improve health care for you, your family, and your community!

You have been asked to participate in a research study of an experimental drug called risankizumab. An investigational drug is one that has not been approved for sale in the United States by the U.S. Food and Drug Administration (FDA). The purpose of this study is to test the safety and effectiveness of two different doses of risankizumab (180 mg and 360 mg). It will be compared to placebo. It is for patients with moderate to severe Hidradenitis Suppurativa.

Drug study, Phase 2
Any, age 18 years or older

Extension Study to Test Effectiveness and Safety of Experimental PF-04965842 for Adolescents With Atopic Dermatitis

Volunteer for research at UC Davis and contribute to discoveries that may improve health care for you, your family, and your community!

You are being asked to take part in this research study because you have moderate to severe atopic dermatitis (AD). This is also known as atopic eczema. The purpose of this research study is to learn about the long-term safety and effectiveness of the study drug, PF-04965842. This study is for participants who previously participated in PF-04965842 AD Phase 3 trials. PF-04965842 is an experimental drug. This means it has not been approved for sale by the FDA. PF-04965842 is a tablet, which is to be taken by mouth and swallowed. PF-04965842 blocks an enzyme called Janus kinase. Janus kinase acts like a switch for the cells of the immune system (the body’s defense against infection and inflammation). By turning off this switch, the cells of the immune system are expected to produce fewer chemicals believed to cause AD. However, there is no guarantee that participating in this study will help your AD.

Drug study, Phase 3
Any, age 12 years or older

Study of Experimental JAK1 Inhibitor With Medicated Topical Therapy in Adolescents With Atopic Dermatitis

Volunteer for research at UC Davis and contribute to discoveries that may improve health care for you, your family, and your community!

You are being asked to take part in this research study because you have atopic dermatitis (AD). This is also known as atopic eczema, which may be of moderate to severe intensity as evaluated by the study doctor. The purpose of this research study is to test the efficacy and safety of two doses of the study drug (PF-04965842). They will be compared to a placebo when taken together with medicated and non-medicated therapy applied to the skin. Researchers will compare the results of taking the higher dose, lower dose, and placebo to see if there are any differences, when taken with the background medication. PF04965842 is an experimental drug. An experimental drug is one that is not approved by the FDA for use in this country. A placebo looks like the study drug but does not contain any active ingredients. Researchers use a placebo to see if the study drug works better or is safer than not taking anything. PF-04965842 is a blocker of an enzyme called Janus kinase (JAK). JAK acts like a switch for the cells of the immune system (the body’s defense against infection and inflammation). By turning off this switch, the cells of the immune system should produce fewer chemicals believed to cause AD. However, there is no guarantee that participating in this study will help your AD.

Drug study, Phase 3
Any, age 12 to 17 years old

Safety and Effectiveness of Experimental Upadacitinib vs. Dupilumab in Adults With Moderate to Severe Atopic Dermatitis

Volunteer for research at UC Davis and contribute to discoveries that may improve health care for you, your family, and your community!

This study will compare the effectiveness and safety of experimental upadacitinib (ABT-494) and dupilumab. This study is for the treatment of adults (18-75 years of age) with moderate to severe atopic dermatitis (AD). This is a double-blinded study. Neither you nor your study doctor will know to which study group you were assigned. In order to keep the study blinded, you will be taking both tablets and injections and you will be assigned to one of the following treatment groups: Upadacitinib 30 mg tablets + placebo pre-filled syringe; OR Dupilumab 300 mg + placebo tablet Placebo pre-filled syringe is a syringe without any active substance that looks like dupilumab. Placebo tablet is a pill without any active substance that looks like upadacitinib.

Drug study, Phase 3
Any, age 18 to 75 years old

Effectiveness and Safety of Experimental Secukinumab Doses in Patients 90kg-or-greater with Severe Chronic Plaque-type Psoriasis

Volunteer for research at UC Davis and contribute to discoveries that may improve health care for you, your family, and your community!

This study will test a higher dose of experimental secukinumab. We hope to learn if it is safe and effective in psoriasis patients with higher body weight. It will compare the following two treatment groups: - a secukinumab low dose group (alternating doses of 300 mg secukinumab and placebo every 2 weeks) and - a secukinumab high dose group (300 mg every 2 weeks). A placebo is a dummy drug with no active medicine inside. Treatment will be delivered using pre-filled syringes. You can find more information about the study treatment in Section 4.2. below titled “What happens during study treatment?” Secukinumab is a medicine which has been approved by the FDA for the treatment of people with your medical condition. The 300 mg every 4 weeks dose being tested in this study is the approved dose (available for you to receive a prescription for) in the United States. The 300 mg every 2 weeks dosing regimen being tested in this study is not currently approved. Secukinumab is a type of medication called a human monoclonal antibody. Monoclonal antibodies are proteins that recognize and bind to other specific proteins. In this case, immune system hormones called “cytokines” that your body produces. The cytokine is a “messenger” protein in the body. Secukinumab binds to it and reduces the activity of interleukin-17A (IL-17A). IL-17A is believed to be partly responsible for inflammation (pain, swelling, redness). Researchers believe that IL-17A causes symptoms of plaque-type psoriasis.

Drug study, Phase 3
Any, age 18 years or older

A Study of Experimental Baricitinib (LY3009104) for Moderate to Severe Atopic Dermatitis

Volunteer for research at UC Davis and contribute to discoveries that may improve health care for you, your family, and your community!

The main reason for you to take part in this study is to help in answering the following research questions: How experimental baricitinib (LY3009104) compares with placebo in helping patients with atopic eczema. The safety of baricitinib and any side effects you might have when you take it. “Experimental” means that the drug being tested has not been approved for routine clinical use or for the use described in this study by the FDA. The FDA is allowing the use of this drug for research.

Drug study, Phase 3
Any, age 18 years or older

A Study of Experimetnal VarIthena on Wound Healing in Venous Leg Ulcers (VLU)

Volunteer for research at UC Davis and contribute to discoveries that may improve health care for you, your family, and your community!

The purpose of this registry is to look at how experimental Varithena® injectable foam works. It will be given to patients who have chronic venous insufficiency (commonly known as “varicose veins”) with leg wounds. The decision to provide you with such medication has been left up to your treating physician and is not being driven by or impacted by this study. The purpose of this project is to collect data about your leg wounds. We hope to learn the impact of treatment on the rate of healing, the rate of repeated wounds, as well as the impacts to your level of pain and quality of life.

Drug study
Any, age 18 years or older

A Study of Experimental Upadacitinib in Adolescents and Adults With Moderate to Severe Atopic Dermatitis (Eczema)

Volunteer for research at UC Davis and contribute to discoveries that may improve health care for you, your family, and your community!

This study will test the effectiveness and safety of the experimental study drug upadacitinib (ABT-494). It will be compared to a placebo, which is an inactive substance that looks like the study drug. Experimental ABT-494 is being tested for the treatment of moderate to severe atopic dermatitis (AD). The study drug is an oral medication (taken by mouth) that is a tablet taken once a day. An experimental drug is one that has not been approved by the FDA.

Drug study, Phase 3
Any, age 12 to 75 years old

A Study of the Experimental Prevena™ device (Incisional Negative Pressure Wound Therapy) for Soft Tissue Sarcoma Wounds

Volunteer for research at UC Davis and contribute to discoveries that may improve health care for you, your family, and your community!

Patients with sarcomas (tumor in bone or soft tissue) who receive radiation before surgery have a greater chance of complications in wound healing. This research study will test a wound dressing called Negative Pressure Wound Therapy (NPWT). NPWT is a wound sponge attached to a gentle suction device. It is more effective at preventing infection of the surgical wound than standard dry gauze wound dressing. The Prevena™ device (NPWT) is FDA approved for use on incisions. This will be considered the investigational dressing. The NPWT device is a foam sponge that is placed over the incision after surgery, and provides a low pressure gentle suction on the wound. It is sealed with an adhesive dressing. The traditional standard dry gauze dressing will be considered the control dressing for this study

Device study
Any, age 18 years or older
Loading